Navigation Links
Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
Date:6/7/2008

t. To reduce this possibility, the dose of sulfonylurea medicine may need to be reduced while using BYETTA. Other common side effects with BYETTA include nausea, vomiting, diarrhea, dizziness, headache, feeling jittery, and acid stomach. Nausea is the most common side effect when first starting BYETTA, but decreases over time in most patients.

If patients experience the following severe and persistent symptoms (alone or in combination): abdominal pain, nausea, vomiting, or diarrhea, they should talk to their healthcare provider because these symptoms could be signs of serious medical conditions. BYETTA may reduce appetite, the amount of food eaten, and body weight. No changes in dose are needed for these side effects. These are not all of the side effects from use of BYETTA. A healthcare provider should be consulted about any side effect that is bothersome or does not go away.

For full prescribing information, visit http://www.BYETTA.com.

About Amylin and Lilly

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first- in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California with over 2,000 employees nationwide. Further information about Amylin Pharmaceuticals is available at http://www.amylin.com.

Through a long-standing commitment to diabetes care, Lilly provides patients with breakthrough treatments that enable them to live longer, healthier and fuller lives. Since 1923, Lilly has been the industry leader in pioneering
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity Without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)
2. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
3. Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
4. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
5. New Eloxatin(R) (oxaliplatin injection) Prescribing Information in the U.S. Includes Six-Year Overall Survival Data
6. Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001 (Sodium Sulfide) for Injection
7. New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma
8. Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study
9. CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model
10. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
11. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... Introduction of new ... tools for radiosurgery/SBRT   The "Elements" ... enhancing the workflow for difficult to treat indications ... - comes full circle with the introduction of ... Elements enable on-the-fly generation of consistent treatment plans ...
(Date:4/24/2015)... Hi-Tech Pharmaceuticals refutes the results from ... of reliable scientific principles and methods and therefore ... of adulteration. The FDA is resting its very, ... misguided hope, that Methylphenylethylamine is not found in ... multiple other studies and cannot be relied on ...
(Date:4/24/2015)... , April 24, 2015 Hospira, ... in the development of biosimilar therapies, spoke about the ... at the European Generics Association (EGA) annual European Biosimilars ... The company also announced the publication of a ... to achieving the full promise of biosimilars." ...
Breaking Medicine Technology:Brainlab Introduces New Generation of VMAT* for Brain and Spine at 3rd ESTRO in Barcelona 2Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 2Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 3Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 4Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 5Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 6Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 2Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 3Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 4Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 5Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 6Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 7
(Date:4/24/2015)... 24, 2015 As the nation recognizes ... unique sacrifices of these young men and women, the ... Veterans and their Families” presents a special training session ... to gain a better understanding of the effect of ... For those – civilian and military – who provide ...
(Date:4/24/2015)... TX (PRWEB) April 24, 2015 The Fastest ... Long, after their great success of the Xtreme Fat Loss ... industry. The fat loss blueprint that claims to help ... the attention of HealthyandFitZone.com's Stan Stevenson, prompting an investigative review. ... shows that the creators spent years researching and experimenting with ...
(Date:4/24/2015)... On February 21st, 2015, Per Wickstrom had ... ItsNotAboutMe.TV contributor Karen Salkin at Durkin Entertainment’s EcoLuxe Lounge, ... addiction, of which Wickstrom is the founder. Making appearances ... the EcoLuxe Lounge is a gathering of some of ... products and services. Among the many roles that she ...
(Date:4/24/2015)... Carinsurancequotesinfo.com has released a new blog ... to qualify for auto insurance as a ... auto insurance online, without having to follow a special ... parents can reduce their auto insurance expenses. The tips ... explained. , Clients can now visit an insurance ...
(Date:4/24/2015)... 2015 Olive Fertility Centre is proud ... and co-director, has been honoured for his pioneering work ... of Hope Gala. , “We are very pleased ... who has been at the forefront of fertility research ... Séguin, Executive Director of Fertile Futures--a Canadian non-profit organization ...
Breaking Medicine News(10 mins):Health News:Coalition Presents Resiliency Training to Raise Awareness during Month of the Military Child (#MOTMC2015) 2Health News:Fastest Fat Loss Week Ever Review Revealed on Healthy & Fit Zone 2Health News:Karen Salkin Talks with Per Wickstrom at the 2015 EcoLuxe Lounge and the "Salute to the Oscars" Celebration 2Health News:Auto Insurance Discounts for Single Parents - How to Qualify for Low Rates 2Health News:Olive Fertility Centre Co-founder, Dr Al Yuzpe, Recognized as a Pioneer in Fertility Preservation 2
... the aftereffects of a chlorine gas disaster in a South ... to expect and how to prepare emergency response systems for ... The study is now available in the January 2009 issue ... , "This is one of the largest community exposures to ...
... symptoms are highly prevalent in different geographic populations ... the lives of those affected. Examples include GERD, ... These problems have an impact on the individual,s ... community-based research evaluating the impact of chronic gastrointestinal ...
... Multi-Serve Canisters Make it Easy to Mix with Water ... 2009 quickly approaches, Americans will begin making New Year,s ... According to this year,s survey from FranklinCovey Products ... licensee of consumer products for FranklinCovey Co, , ...
... Fisher Vista, LLC has reported,its seventh consecutive year of ... core product HRmarketer.com and strong demand for media,relations and ... The HRmarketer Services Group, established ... Services Group provides HR vendors with a,one-stop source for ...
... ARAY ), a global leader in the ... scheduled to present at the 11th Annual Needham Growth ... 2009 at 11:00 a.m. EST (8:00 a.m. PST).A live ... the investor relations page of the Company,s Web site ...
... Walks Drive Home Importance of Awareness and Education of ... effort to raise money for The Kidney TRUST(TM) -- ... chronic kidney disease (CKD) -- DaVita Inc., the nation,s ... the 3rd annual "Kidney Awareness Time(TM)" Walk-a-thon (The KAT ...
Cached Medicine News:Health News:New study examines effects of Graniteville, S.C., chlorine gas disaster 2Health News:New study examines effects of Graniteville, S.C., chlorine gas disaster 3Health News:Chronic gastrointestinal symptoms in Korean population 2Health News:Ocean Spray(R) Announces Sugar-Free Drink Mixes - A Sweet Way for Dieters to 'Stick' to Their Resolutions 2Health News:Fisher Vista, LLC Reports Seventh Consecutive Year of Revenue Growth and Profitability 2Health News:Accuray Incorporated to Present at 11th Annual Needham Growth Stock Conference 2Health News:Thousands of DaVita Teammates Raise Over $100,000 for CKD Programs 2Health News:Thousands of DaVita Teammates Raise Over $100,000 for CKD Programs 3